Ranbaxy to sell Avessa for asthma in India

By Lisa Kerner

Charlotte, N.C., Sept. 12 - Ranbaxy Laboratories Ltd. launched its Avessa (formoterol + fluticasone) inhalation capsules in India for the treatment of asthma.

Avessa, available as Rheocaps Avessa 100 mcg, 250 mcg or 500 mcg, is used with the Rheohaler capsule-based multi-dose dry powder inhaler.

The company launched its Osonide (Ciclesonide) inhaler, a once-a-day product for asthma, earlier this year.

Ranbaxy, based in Haryana, India, is a research-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.